IPL for Dry Eye and MGD

IPL stands for intense pulsed light. It is not a laser. A laser typically produces light within a narrow wavelength range. IPL produces high-intensity pulses containing a broad spectrum of wavelengths, with filters used to select the range delivered to the skin.

IPL has been used in dermatology for many years, particularly for conditions involving pigmentation, superficial blood vessels and rosacea. Its use for dry eye developed later. Today, IPL is included among the in-office treatments used for MGD in the TFOS DEWS III management report.

The connection initially came from dermatology. Clinicians treating facial rosacea with IPL noticed that some patients also reported improvement in their dry-eye symptoms. That observation eventually led researchers to investigate IPL specifically for MGD and ocular-surface disease.

This history matters because it gives us an important clue: IPL was not originally designed as a machine for heating meibomian glands. Its biological effects on skin and superficial blood vessels were already being used for other reasons. The possible effects on MGD came later.

Ocular Rosacea and Dry Eye

This is where things become complicated. There is no single proven mechanism that completely explains IPL’s effects on MGD. A 2024 clinical review states explicitly that although randomized trials have demonstrated improvements in meibomian gland function and tear-film outcomes, the mechanism of action remains unclear.

Several mechanisms have been proposed. They include effects on abnormal superficial blood vessels, inflammatory pathways, meibomian gland secretion, Demodex and microorganisms, and possibly other biological processes. Let’s separate them.

1. Abnormal blood vessels and inflammation

One of the most interesting proposed mechanisms comes directly from IPL’s dermatological use. Rosacea and some forms of lid-margin disease can involve visible superficial blood vessels or telangiectasia. IPL energy can be absorbed by hemoglobin in blood vessels. That can produce controlled thermal effects within selected superficial vessels. This is sometimes described as photothermolysis.

The idea in MGD is that abnormal periocular vessels may contribute to the inflammatory environment by carrying or releasing inflammatory mediators. Reducing those vessels could therefore potentially reduce part of that inflammatory input. This mechanism is biologically plausible and consistent with IPL’s established vascular effects in dermatology.

But it should not be simplified into:

“IPL removes inflammation.”

Inflammation is a complex biological process, not something contained entirely inside visible blood vessels.

2. Does IPL actually reduce inflammatory mediators?

There is evidence that inflammatory markers can change after IPL. Studies have reported changes in tear cytokines and other inflammatory markers following treatment. For example, clinical research has reported reductions in inflammatory mediators including IL-6 and other cytokines after IPL treatment in MGD. That supports the idea that IPL may influence the inflammatory environment.

But there is an important distinction: observing reduced inflammatory markers after treatment does not necessarily prove exactly how IPL caused that reduction. The effect could involve vascular changes, improved gland function, changes in the ocular-surface environment, or several mechanisms simultaneously.

So “IPL appears capable of influencing inflammation” is more defensible than “we know exactly how IPL treats inflammation.”

3. Does IPL heat the meibomian glands?

Heat is another proposed mechanism. IPL energy delivered to tissue produces thermal effects. It has therefore been suggested that this heating may increase meibum fluidity, making abnormal secretion easier to express. That is plausible.

But we need to be careful here because IPL is sometimes explained as though it were simply a very sophisticated warm compress. It isn’t. If the entire therapeutic effect were simply “heat the meibum, make it fluid, squeeze it out,” we would have difficulty explaining why IPL’s vascular and inflammatory effects are discussed so extensively.

Current reviews describe the mechanism as multifactorial and incompletely understood rather than simply thermal. So heating may contribute. It should not automatically be presented as the mechanism.

Warm Compresses & Heat for MGD: what simple heat does

4. What about Demodex?

IPL has also been proposed to affect Demodex mites, which can contribute to blepharitis and MGD in some patients. This is particularly interesting because Demodex-associated disease gives IPL another possible biological target. But again, we should not overstate the evidence.

A 2025 systematic review and meta-analysis included six trials involving 329 adults. IPL showed a trend toward reducing Demodex counts, and eradication rates were higher with IPL, but the certainty of evidence was considered low and the reduction in mite count in RCTs did not reach statistical significance.

So “IPL may affect Demodex” is reasonable. “IPL is a proven Demodex-eradication treatment” would be too strong. And importantly, someone with Demodex now has treatments specifically designed to target the mites.

Demodex Blepharitis and Dry Eye

5. Does IPL kill bacteria?

Antimicrobial effects have also been proposed. Changes in the microbial environment of the lid margin could theoretically reduce inflammatory stimulation. But this is another area where mechanistic hypotheses are stronger than our ability to say exactly how much this contributes to clinical improvement. Again, IPL may be doing several things simultaneously.

This is where we can be much more confident. We now have multiple randomized controlled trials and systematic reviews. A 2024 systematic review included 13 randomized studies of IPL for dry-eye symptoms associated with MGD. Compared with placebo, IPL probably produced a clinically meaningful improvement in symptoms: the pooled difference was approximately 16 points on the OSDI questionnaire. The certainty of this evidence was rated moderate.

So IPL is no longer a treatment supported only by anecdotes or small uncontrolled case series. There is meaningful clinical evidence that it can help some patients with MGD-related dry eye.

But there is an important catch.

This distinction is extremely important. In real life, IPL is often not used instead of everything else. It is added to:

• •warm compresses
• •lubricating drops
• •lid hygiene
• •gland expression
• •or other treatments

When the 2024 systematic review examined IPL as an add-on to standard care, the additional symptom improvement was smaller — about 7 OSDI points — and the authors concluded that it remains unclear whether that additional effect is clinically meaningful. The certainty of evidence for this comparison was very low.

That gives us a much more nuanced picture: IPL can work. But how much additional benefit it provides when someone is already receiving other effective MGD treatment is less certain.

This is another important complication in the literature. Many IPL protocols combine IPL with meibomian gland expression (MGX). For example, a randomized controlled study compared IPL + MGX with sham IPL + MGX. Both groups therefore received expression. The IPL + MGX group showed greater improvement in several outcomes, including tear break-up time. This is useful because it suggests that IPL can contribute something beyond expression alone.

But across the literature, protocols vary substantially. Some studies use IPL alone. Some use IPL + MGX. Some combine IPL with other treatments. That makes a seemingly simple question — “How effective is IPL?” — surprisingly difficult to answer with one number.

Meibomian Gland Expression as Treatment

No. This follows directly from everything we have discussed in this guide. MGD is not one identical biological problem. Imagine someone with significant lid-margin telangiectasia, ocular rosacea, inflammatory MGD and poor-quality meibum. Now imagine someone with little visible inflammation, no rosacea but severe thick obstructive secretion. And another person with extensive structural gland loss and little functioning tissue remaining.

All three may receive the label MGD. But it does not follow that all three should respond identically to IPL. One of the major unanswered questions is still: which patients are most likely to benefit?

No. Clinical studies of IPL for MGD have not universally required patients to have rosacea. For example, prospective studies have specifically enrolled patients with moderate-to-severe MGD without requiring skin rosacea as an inclusion criterion.

So IPL is not simply “a rosacea treatment that happens to help the eyes.” Its clinical use in MGD is broader than that. But rosacea and telangiectatic lid disease may still provide particularly intuitive biological targets for some of IPL’s proposed mechanisms.

This is a claim that deserves considerable caution. Some studies report changes in meibography measurements after IPL. But an apparent improvement in a gland image does not automatically prove that previously destroyed gland tissue has regenerated. Meibography is an imaging technique with limitations in acquisition, segmentation and interpretation.

At present, IPL should primarily be understood as a treatment aimed at improving function, tear-film behavior, symptoms and the inflammatory and lid environment — not as an established method for regrowing lost meibomian glands.

Meibography: what gland images can and can't tell you

There is no single universal protocol. Many studies use a series of treatments, often three or four sessions separated by several weeks. Other protocols differ. Devices differ too. They can use different:

• •wavelength filters
• •energy levels
• •pulse structures
• •treatment areas
• •numbers of flashes

This is important because “I had IPL” does not describe one perfectly standardized intervention. Two clinics may call their procedure IPL while using substantially different protocols.

No. IPL energy settings are not a simple strength scale where more energy means more therapeutic effect. Settings depend partly on:

• •device
• •wavelength filter
• •skin pigmentation
• •treatment location
• •protocol

Melanin also absorbs light energy. That means inappropriate settings can increase the risk of skin injury. So increasing energy because previous sessions “didn’t work enough” is not automatically a rational strategy. Treatment parameters need to remain within the safe protocol for the device and patient.

Yes. This is fundamental to IPL safety. Because melanin absorbs IPL energy, darker skin contains more competing chromophore and can be at greater risk of burns, pigment changes and scarring.

Many dry-eye IPL studies excluded people with Fitzpatrick skin types V and VI. Reviews therefore caution that the evidence base applies predominantly to lighter skin types, and suitability and settings must account for pigmentation. Pigmented lesions, tattoos and some other skin findings in the treatment area can also require special consideration.

This is extremely important. IPL produces powerful light pulses, and ocular structures — particularly pigmented tissues — can absorb this energy. Appropriate eye protection is therefore not optional. Published reviews explicitly state that protective eye shields capable of attenuating IPL wavelengths must be used to prevent potentially serious ocular injury.

Different IPL protocols use different forms of protection depending on where treatment is delivered. Some protocols treat only the skin below the lower eyelids using external shields. Other periocular protocols may use appropriately fitted ocular shields when treating closer to the eyelid itself. These are not interchangeable techniques, and the protective method has to match the treatment area and device protocol.

This statement should be treated very carefully. The important question is not simply metal versus external goggles. It is: where is the IPL being delivered, what protocol is being used, and what eye protection has been validated for that protocol?

Traditional MGD protocols commonly apply IPL to the facial skin below the lower eyelids with protective eye shields in place. Some newer techniques treat closer to the eyelid and therefore use different protective approaches. Moving the treatment closer to the eye changes both the potential target and the safety requirements.

So more aggressive periocular treatment is not automatically more effective treatment. And the choice of protection should not be separated from the protocol itself.

Yes. IPL is delivering enough energy to produce biological effects in tissue. Possible skin-related adverse effects reported in the literature include:

• •pain
• •erythema
• •swelling
• •pigment changes
• •localized hair or eyelash loss
• •and other transient reactions

A large review of published studies reported mostly mild adverse events, but adverse-event reporting was inconsistent across studies. This brings us to an important limitation.

Not as well as we would ideally like. The 2024 systematic review found that the evidence regarding adverse events was very uncertain. Why? Partly because adverse events were inconsistently collected and reported across trials.

That does not mean IPL is known to be highly dangerous. It means that absence of well-recorded harms is not the same thing as strong evidence that harms are rare. That distinction matters.

Suitability depends on the device and protocol, so contraindications should always be checked for the specific system. Clinical trials and reviews commonly exclude or use caution in people with factors such as:

• •certain darker skin types
• •photosensitizing medications
• •active skin disease or injury in the treatment area
• •some pigmented lesions or tattoos in the treatment field
• •recent ocular surgery or trauma
• •pregnancy, among other considerations

This is one reason IPL should not be treated as a cosmetic add-on that happens to be performed near the eyes. It is a medical energy-based procedure requiring appropriate patient selection.

We do not have evidence supporting that claim. Studies commonly assess patients weeks or months after treatment. Some demonstrate persistent improvement over those periods. But MGD is often chronic, and recurrence can occur. Some clinicians therefore use maintenance treatments.

What we do not have is a universal evidence-based rule such as “everyone needs IPL every six months forever.” Maintenance should depend on the patient’s response and the biological problem being treated.

Not automatically. Return to our central question: what are we treating now? Suppose someone originally had significant lid-margin inflammation, poor meibum quality, low expressibility and unstable tears. After treatment those findings improve substantially. Continuing IPL indefinitely simply because “IPL helped before” is not necessarily the same thing as demonstrating that the current eye still has a meaningful IPL target.

Treatment should be reassessed.

Treating Dry Eye: Start With the Target

That does not automatically mean the dry eye is unusually severe or untreatable. Several possibilities exist. The patient may not have had an IPL-responsive driver. MGD may not have been the dominant cause of symptoms. The glands may have substantial structural loss. Another contributor may remain untreated. The protocol may have been inadequate. Or the person may simply not respond meaningfully to IPL. Again: treatment response is information. It is not a verdict on the entire disease.

How to Choose a Dry Eye Treatment

We don’t actually have good evidence for a direct answer. A 2025 systematic review examining IPL and LipiFlow included 12 randomized studies, but none directly compared IPL with LipiFlow. Any apparent difference therefore came from indirect comparisons between separate studies.

So statements such as “IPL is better than LipiFlow” or “LipiFlow is better than IPL” are stronger than the direct comparative evidence currently allows. They target MGD in different ways, and patient selection may ultimately matter more than trying to identify one universal winner.

Thermal Pulsation for MGD

Treating Meibomian Gland Dysfunction: the overview

For the right patient, it can be. Current evidence supports IPL as a legitimate treatment for MGD-related dry eye, and TFOS DEWS III includes it among contemporary in-office MGD therapies. The strongest recent systematic evidence suggests that IPL probably improves dry-eye symptoms compared with placebo.

But that is different from saying that everyone with MGD needs IPL, that IPL cures MGD, or that we completely understand how IPL works. We don’t.